INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
8.02
+0.32 (4.16%)
At close: Jun 16, 2025, 4:00 PM
8.01
-0.01 (-0.12%)
After-hours: Jun 16, 2025, 5:13 PM EDT
INmune Bio Stock Forecast
Stock Price Forecast
The 3 analysts that cover INmune Bio stock have a consensus rating of "Strong Buy" and an average price target of $24.33, which forecasts a 203.37% increase in the stock price over the next year. The lowest target is $20 and the highest is $30.
Price Target: $24.33 (+203.37%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 13, 2025.
Analyst Ratings
The average analyst rating for INmune Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | +274.06% | Feb 13, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $22 → $23 | Buy | Maintains | $22 → $23 | +186.78% | Feb 11, 2025 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +149.38% | Oct 21, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $22 | Buy | Initiates | $22 | +174.31% | Aug 22, 2024 |
| Baird | Baird | Buy Initiates $16 | Buy | Initiates | $16 | +99.50% | Jun 1, 2023 |
Financial Forecast
Revenue This Year
n/a
from 14.00K
Revenue Next Year
7.36M
EPS This Year
-1.78
from -2.11
EPS Next Year
-1.73
from -1.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 15.2M | 25.5M | ||
| Avg | n/a | 7.4M | 22.6M | ||
| Low | n/a | 2.2M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 246.6% | ||
| Avg | - | - | 207.0% | ||
| Low | - | - | 166.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.61 | -1.18 | -0.83 | ||
| Avg | -1.78 | -1.73 | -1.32 | ||
| Low | -1.94 | -2.16 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.